U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Clear Cell Adenocarcinoma

MedGen UID:
1791623
•Concept ID:
C5555182
•
Neoplastic Process

Definition

Ovarian clear cell adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Ovarian Clear Cell Adenocarcinoma

Professional guidelines

PubMed

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T
Mol Cancer Ther 2010 Aug;9(8):2411-22. Epub 2010 Jul 27 doi: 10.1158/1535-7163.MCT-10-0169. PMID: 20663925Free PMC Article
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ
Ann Oncol 2001 Dec;12(12):1705-9. doi: 10.1023/a:1013558501425. PMID: 11843248

Recent clinical studies

Etiology

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T
Eur J Obstet Gynecol Reprod Biol 2013 Sep;170(1):259-63. Epub 2013 Jul 20 doi: 10.1016/j.ejogrb.2013.06.035. PMID: 23880598
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD
Clin Cancer Res 2011 Apr 15;17(8):2538-48. Epub 2011 Feb 22 doi: 10.1158/1078-0432.CCR-10-3314. PMID: 21343371
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N
Int J Gynecol Cancer 2006 Jan-Feb;16(1):52-6. doi: 10.1111/j.1525-1438.2006.00289.x. PMID: 16445610

Diagnosis

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.
Lin YC, Wen KC, Sung PL, Chou YT, Liew PL, Chen LY, Huang RL, Lai HC, Chang LT
J Ovarian Res 2020 Dec 8;13(1):143. doi: 10.1186/s13048-020-00751-3. PMID: 33292376Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article
Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.
Yoon H, Choi YL, Song JY, Do I, Kang SY, Ko YH, Song S, Kim BG
PLoS One 2014;9(2):e88587. Epub 2014 Feb 11 doi: 10.1371/journal.pone.0088587. PMID: 24523919Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y
Int J Gynecol Cancer 2008 Sep-Oct;18(5):937-42. Epub 2007 Dec 13 doi: 10.1111/j.1525-1438.2007.01158.x. PMID: 18081792

Therapy

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ, Yoon A, Ryu JY, Cho YJ, Choi JJ, Song SY, Bang H, Lee JS, Cho WC, Choi CH, Lee JW, Kim BG, Bae DS
Sci Rep 2016 Dec 5;6:38502. doi: 10.1038/srep38502. PMID: 27917934Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD
Clin Cancer Res 2011 Apr 15;17(8):2538-48. Epub 2011 Feb 22 doi: 10.1158/1078-0432.CCR-10-3314. PMID: 21343371
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.
Rauh-Hain JA, Penson RT
Int J Gynecol Cancer 2008 Sep-Oct;18(5):934-6. Epub 2007 Dec 13 doi: 10.1111/j.1525-1438.2007.01156.x. PMID: 18081793

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M, Koh I, Nakamoto K, Nosaka S, Tomono K, Sugimoto J, Kudo Y
Anticancer Res 2023 Jun;43(6):2509-2517. doi: 10.21873/anticanres.16418. PMID: 37247931
Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy.
Ma B, Zhao L, Zhang Y, Zhang F, Gao Q
Immunotherapy 2022 Oct;14(15):1205-1209. Epub 2022 Aug 31 doi: 10.2217/imt-2021-0328. PMID: 36043370
The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.
Su KM, Lin TW, Liu LC, Yang YP, Wang ML, Tsai PH, Wang PH, Yu MH, Chang CM, Chang CC
Int J Mol Sci 2020 Apr 17;21(8) doi: 10.3390/ijms21082824. PMID: 32316695Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M, Koh I, Nakamoto K, Nosaka S, Tomono K, Sugimoto J, Kudo Y
Anticancer Res 2023 Jun;43(6):2509-2517. doi: 10.21873/anticanres.16418. PMID: 37247931
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.
Lin YC, Wen KC, Sung PL, Chou YT, Liew PL, Chen LY, Huang RL, Lai HC, Chang LT
J Ovarian Res 2020 Dec 8;13(1):143. doi: 10.1186/s13048-020-00751-3. PMID: 33292376Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y
Int J Gynecol Cancer 2008 Sep-Oct;18(5):937-42. Epub 2007 Dec 13 doi: 10.1111/j.1525-1438.2007.01158.x. PMID: 18081792

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...